Neurocrine Biosciences, Inc. Stock Sao Paulo
Equities
N1BI34
BRN1BIBDR009
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
36.4 BRL | +6.25% | +1.79% | +12.69% |
Sales 2024 * | 2.22B 11.94B 3.05B | Sales 2025 * | 2.55B 13.72B 3.5B | Capitalization | 13.63B 73.32B 18.72B |
---|---|---|---|---|---|
Net income 2024 * | 431M 2.32B 592M | Net income 2025 * | 675M 3.63B 927M | EV / Sales 2024 * | 5.24 x |
Net cash position 2024 * | 2B 10.76B 2.75B | Net cash position 2025 * | 2.81B 15.12B 3.86B | EV / Sales 2025 * | 4.24 x |
P/E ratio 2024 * |
33.4
x | P/E ratio 2025 * |
21.4
x | Employees | 1,448 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.2% |
Latest transcript on Neurocrine Biosciences, Inc.
1 day | +6.25% | ||
1 week | +1.79% | ||
Current month | +2.94% | ||
1 month | +0.78% | ||
3 months | +3.62% | ||
6 months | +22.68% | ||
Current year | +12.69% |
Managers | Title | Age | Since |
---|---|---|---|
Kevin Gorman
FOU | Founder | 66 | 91-12-31 |
Director of Finance/CFO | 44 | 17-10-31 | |
Jude Onyia
CTO | Chief Tech/Sci/R&D Officer | 60 | 21-11-29 |
Members of the board | Title | Age | Since |
---|---|---|---|
Stephen Sherwin
BRD | Director/Board Member | 75 | 99-03-31 |
George Morrow
BRD | Director/Board Member | 72 | 15-09-30 |
Kevin Gorman
FOU | Founder | 66 | 91-12-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-06-14 | 36.4 | +0.89% | 3,000 |
24-06-10 | 36.08 | +0.89% | 346 |
24-06-07 | 35.76 | +3.44% | 2 |
Delayed Quote Sao Paulo, June 14, 2024 at 02:32 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+18.15% | 124B | |
+18.02% | 112B | |
+5.07% | 22.94B | |
-12.75% | 22.22B | |
-9.86% | 17.02B | |
-14.97% | 16.88B | |
-39.94% | 16.87B | |
+27.39% | 11.61B | |
+106.26% | 10.31B |
- Stock Market
- Equities
- NBIX Stock
- N1BI34 Stock